Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.

European radiology - 1 Jan 2018

Zhu Yong, Chen Jun, Kong Weiwei, Mao Liang, Kong Wentao, Zhou Qun, Zhou Zhengyang, Zhu Bin, Wang Zhongqiu, He Jian, Qiu Yudong

Abstract excerpt

OBJECTIVES: To explore the difference in contrast-enhanced computed tomography (CT) features of intrahepatic cholangiocarcinomas (ICCs) with different isocitrate dehydrogenase (IDH) mutation status. METHODS: Clinicopathological and contrast-enhanced CT features of 78 patients with 78 ICCs were retrospectively analysed and compared based on IDH mutation status. RESULTS: There were 11 ICCs with IDH mutation (11/78,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Ducts, Intrahepatic

Share to Cholangiocarcinoma

Share to Contrast Media

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 28752218
DOI: 10.1007/s00330-017-4957-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.PMID 28752218Read ↗

Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Mutation Rate of IDH1 and the Impact of Pathological Features on Survival in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Molecular Profile of Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.Semantic proximity Read ↗

Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.Semantic proximity Read ↗

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinomaSemantic proximity Read ↗

Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.Semantic proximity Read ↗

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma cells to MDM2 inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.